Phyllopharma

Traditionally, protein drugs, such as insulin, have been delivered as sterile injections, requiring cold storage/transportation, thereby decreasing patient affordability and compliance. In order to address these challenges, PhylloPharma is developing oral delivery systems through encapsulation of protein drugs in plant cells. Plant cells are now being developed as a novel strategy to deliver protein drugs, with initial applications in the treatment of several viral diseases (including SARS-CoV-2, Influenza, CMV, EBV, Hepatis C virus, Herpes viruses).